Medobeta (Betamethasone)

Betamethasone binds to intracellular glucocorticoid receptors in skin cells. The resulting complex alters gene transcription, decreasing the production of inflammatory cytokines and mediators while increasing anti‑inflammatory proteins, which together suppress local inflammation and immune responses.

The appropriate dose and frequency of Medobeta are determined by the prescribing healthcare professional based on the specific skin condition, severity, patient age and treatment area. Patients should follow the prescriber’s instructions and not adjust the regimen on their own.

Safety of topical betamethasone in pregnancy or while breastfeeding has not been definitively established. Healthcare providers should weigh potential benefits against risks and consider alternative therapies when possible. Patients should discuss their situation with a qualified clinician before use.

To request Medobeta, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Medobeta’s active ingredient, betamethasone, is a high‑potency glucocorticoid, offering stronger anti‑inflammatory effects than lower‑potency steroids such as hydrocortisone. Compared with other high‑potency options like clobetasol, betamethasone provides similar efficacy but may differ in formulation, skin penetration and tolerability profiles.

Medobeta should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from excessive heat, moisture and direct sunlight to maintain stability and potency.

Medobeta is applied topically to the affected skin area. A thin layer is gently rubbed in until it disappears, usually once or twice daily as directed by the prescriber. Hands should be washed before and after application, and contact with eyes, mouth or open wounds should be avoided.

Serious risks include skin atrophy, telangiectasia, hypopigmentation, secondary infections, and systemic effects such as adrenal suppression when large areas are treated for prolonged periods. Patients should report any unusual skin changes, signs of infection or systemic symptoms to their healthcare provider promptly.

Medobeta should be avoided in individuals with known hypersensitivity to betamethasone or any formulation excipients, in patients with untreated skin infections at the application site, and in those where systemic corticosteroid exposure is contraindicated unless specifically directed by a physician.